Media Summary: Matthew Zirwas, MD, provides advice to dermatologists discussing the In this video, Prof. Christopher Bunick discusses the 6-year long-term Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding ...

The Jak Inhibitor Safety Conversation - Detailed Analysis & Overview

Matthew Zirwas, MD, provides advice to dermatologists discussing the In this video, Prof. Christopher Bunick discusses the 6-year long-term Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding ... Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an indirect treatment ... In this video, Prof. Christopher Bunick provides an in-depth discussion of special interest adverse events associated with International Dermatology Foundation Educational Series Webinar: A Once-Daily Oral

Visit to access the activity, download resources and earn CE/CME credits. This video ... In the second installment of a two-part episode of Prescribing Hope in AD, Christopher Bunick, MD, PhD, an Associate Professor ... In this video, Dr. Diego Ruiz Dasilva from Eastern Virginia Medical School shares key insights on the application of Brad Glick, DO, MPH, FAAD provides an update on the field of

Photo Gallery

The JAK Inhibitor Safety Conversation
Long-term Safety of JAK Inhibitors | Research Interview | AAD 2026
Top 3 Messages About JAK Inhibitor Safety
An indirect comparison of the safety profiles of JAK inhibitors in patients with myelofibrosis
JAK Inhibitor Black Box Warning: What Dermatologists Need to Know
Special Interest Adverse Events of JAK Inhibitors | Research Interview | AAD 2026
The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)
IDEF Educational Series Webinar  A Once Daily Oral JAK Inhibitor for Adults With Moderate to Severe
JAK Inhibitor Safety and Efficacy - Psoriatic Arthritis Posters and Abstracts from San Diego
New JAK Inhibitor for Ankylosing Spondylitis: Ivarmacitinib Phase 2/3 Trial Results
In Search of Non-steroidal Alternatives for AD: How Do Topical JAK inhibitors Fit In?
Application of JAK Inhibitors in Dermatology | Research Interview | AAD 2026
View Detailed Profile
The JAK Inhibitor Safety Conversation

The JAK Inhibitor Safety Conversation

Matthew Zirwas, MD, provides advice to dermatologists discussing the

Long-term Safety of JAK Inhibitors | Research Interview | AAD 2026

Long-term Safety of JAK Inhibitors | Research Interview | AAD 2026

In this video, Prof. Christopher Bunick discusses the 6-year long-term

Top 3 Messages About JAK Inhibitor Safety

Top 3 Messages About JAK Inhibitor Safety

Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding ...

An indirect comparison of the safety profiles of JAK inhibitors in patients with myelofibrosis

An indirect comparison of the safety profiles of JAK inhibitors in patients with myelofibrosis

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an indirect treatment ...

JAK Inhibitor Black Box Warning: What Dermatologists Need to Know

JAK Inhibitor Black Box Warning: What Dermatologists Need to Know

Are

Special Interest Adverse Events of JAK Inhibitors | Research Interview | AAD 2026

Special Interest Adverse Events of JAK Inhibitors | Research Interview | AAD 2026

In this video, Prof. Christopher Bunick provides an in-depth discussion of special interest adverse events associated with

The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)

The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)

Dr.

IDEF Educational Series Webinar  A Once Daily Oral JAK Inhibitor for Adults With Moderate to Severe

IDEF Educational Series Webinar A Once Daily Oral JAK Inhibitor for Adults With Moderate to Severe

International Dermatology Foundation Educational Series Webinar: A Once-Daily Oral

JAK Inhibitor Safety and Efficacy - Psoriatic Arthritis Posters and Abstracts from San Diego

JAK Inhibitor Safety and Efficacy - Psoriatic Arthritis Posters and Abstracts from San Diego

Visit http://annenberg.net/Psoriatic-Arthritis-CE to access the activity, download resources and earn CE/CME credits. This video ...

New JAK Inhibitor for Ankylosing Spondylitis: Ivarmacitinib Phase 2/3 Trial Results

New JAK Inhibitor for Ankylosing Spondylitis: Ivarmacitinib Phase 2/3 Trial Results

Can a selective JAK1

In Search of Non-steroidal Alternatives for AD: How Do Topical JAK inhibitors Fit In?

In Search of Non-steroidal Alternatives for AD: How Do Topical JAK inhibitors Fit In?

In the second installment of a two-part episode of Prescribing Hope in AD, Christopher Bunick, MD, PhD, an Associate Professor ...

Application of JAK Inhibitors in Dermatology | Research Interview | AAD 2026

Application of JAK Inhibitors in Dermatology | Research Interview | AAD 2026

In this video, Dr. Diego Ruiz Dasilva from Eastern Virginia Medical School shares key insights on the application of

What You Should Know About JAK Inhibitors in Dermatology

What You Should Know About JAK Inhibitors in Dermatology

Brad Glick, DO, MPH, FAAD provides an update on the field of